# AVITA Medical, Inc.: Form 10-Q for the period ended Jun 30, 2022

- Company: [AVITA Medical, Inc.](/companies/rcel.md) (CIK 1762303)
- Form: 10-Q
- Filed: 2022-08-11
- Accepted by EDGAR: Aug 11, 2022, 16:12 ET
- Period: 2022-06-30
- Accession: 0001564590-22-029124
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1762303/000156459022029124/rcel-10q_20220630.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1762303/000156459022029124/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2022-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2022-04-01 to 2022-06-30 | $8.3m | us-gaap:Revenues |
| Revenue | 6 months, 2022-01-01 to 2022-06-30 | $15.9m | us-gaap:Revenues |
| Cost of revenue | 3 months, 2022-04-01 to 2022-06-30 | $1.4m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months, 2022-01-01 to 2022-06-30 | $3.2m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2022-04-01 to 2022-06-30 | $6.9m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2022-01-01 to 2022-06-30 | $12.7m | us-gaap:GrossProfit |
| Research and development | 3 months, 2022-04-01 to 2022-06-30 | $3.1m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2022-01-01 to 2022-06-30 | $6.7m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2022-04-01 to 2022-06-30 | −$6.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2022-01-01 to 2022-06-30 | −$15.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2022-04-01 to 2022-06-30 | $4.0k | us-gaap:InterestExpense |
| Interest expense | 6 months, 2022-01-01 to 2022-06-30 | $4.0k | us-gaap:InterestExpense |
| Income tax | 3 months, 2022-04-01 to 2022-06-30 | $4.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2022-01-01 to 2022-06-30 | $8.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2022-04-01 to 2022-06-30 | −$6.3m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2022-01-01 to 2022-06-30 | −$15.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2022-04-01 to 2022-06-30 | $0.25 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2022-01-01 to 2022-06-30 | $0.63 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2022-04-01 to 2022-06-30 | $0.25 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2022-01-01 to 2022-06-30 | $0.63 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2022-04-01 to 2022-06-30 | 24,971,243 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2022-01-01 to 2022-06-30 | 24,954,712 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2022-01-01 to 2022-06-30 | −$12.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2022-01-01 to 2022-06-30 | $278.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2022-06-30 | $34.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2022-06-30 | $91.8m | us-gaap:AssetsCurrent |
| Total assets | at 2022-06-30 | $102.7m | us-gaap:Assets |
| Current liabilities | at 2022-06-30 | $7.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2022-06-30 | $9.9m | us-gaap:Liabilities |
| Shareholders' equity | at 2022-06-30 | $92.6m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 27,341 characters.

*The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q.*

*Our actual results and timing of certain events may differ materially from the results discussed, projected, anticipated, or indicated in any forward-looking statements. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this Quarterly Report on Form 10-Q. In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this Quarterly Report on Form 10-Q, they may not be predictive of results or developments in future periods.*

*The following information and any forward-looking statements should be considered in light of factors discussed elsewhere in this Quarterly Report on Form 10-Q, including those risks identified under Part II, Item 1A. Risk Factors.*

*We caution readers not to place undue reliance on any forward-looking statements made by us, which speak only as of the date they are made. We disclaim any obligation, except as specifically required by law and the rules of the SEC and the ASX, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.*

### Overview

The AVITA group of companies (comprising AVITA Medical, Inc. (“AVITA” or the “Company”) and its subsidiaries, including AVITA Medical Pty Limited, previously known as AVITA Medical Limited, (“AVITA Medical”)) (collectively, “AVITA Group” or “we”, “us”, or “our”) is a commercial-stage regenerative medicine company focused on the treatment of burns, trauma and other acute injuries, together with skin defects like vitiligo. The Company’s lead product is the RECELL® System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin™ Cells using a small sample of the patient’s own skin. In September 2018, the United States Food & Drug Administration (“FDA”) granted premarket approval (“PMA”) to the RECELL System for use in the treatment of acute thermal burns in patients eighteen years and older. Following receipt of our original PMA, we commenced commercializing the RECELL System in January 2019 in the United States. In 2021 FDA expanded the approval to include pediatric acute full-thickness thermal burns. In February 2022, the FDA approved a PMA supplement for the RECELL® Autologous Cell Harvesting Device with enhanced ease-of-use, aimed at providing clinicians a more efficient user experience and simplified workflow. In addition, the FDA has granted the Company Investigational Device Exemptions (“IDEs”) which have enabled the Company to initiate pivotal clinical trials to further expand the approval of the RECELL System for soft tissue reconstruction and vitiligo. Enrollment of those clinical trials is complete, with topline results recently announced for the soft tissue reconstruction trial. Results from those studies are intended to support the Company’s pursuit of FDA approval to market the RECELL System in the United States for those indications.

The RECELL System is used to prepare Spray-On Skin Cells using a small amount of a patient’s own skin, providing a new way to treat severe burns, and simultaneously significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care as a standalone product, or in combination with “skin grafts”, known as split-thickness skin autografts, depending on the depth of the burn injury. The pivotal studies leading to the RECELL System’s FDA PMA for the treatment of acute thermal burns, demonstrated that the RECELL System treated burns using 97.5 percent less donor skin when used alone in second-degree burns, and 32 percent less donor skin when used with autograft for third-degree burns compared to standard of care autografting. In these studies, a statistically significant reduction in donor skin required to treat burn patients with the RECELL System was realized without any associated compromise to healing or safety outcomes. Donor site outcomes from the clinical trial for second-degree burns also revealed a statistically significant reduction in patient-reported pain, increased patient satisfaction and improved scar outcomes.

Our compelling data from prospective, randomized, controlled clinical trials conducted at major United States burn centers, health economics modeling, and real-world use globally demonstrate that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings.

The RECELL System is Therapeutic Goods Administration (“**TGA”**) registered in Australia cleared for use in the treatment of burns, acute wounds, scars and vitiligo. In Europe, the RECELL System received CE-mark approval for the treatment of burns, acute wounds, chronic wounds, scars and vitiligo. In February 2019, our marketing partner COSMOTEC filed a Japan’s

Pharmaceuticals and Medical Devices Act (“PMDA”) application for approval to market the RECELL System in Japan for the treatment of burns and other wounds. In February 2022, COSMOTEC’s application for regulatory approval was approved by the PMDA with labelling for treatment of burns. Presently, we are not actively marketing the RECELL System internationally and therefore do not derive meaningful revenue from the RECELL System in these markets.

Our website address is www.avitamedical.com. Information contained on our website is not part of or incorporated into this report. We make our periodic reports, together with any amendments, available on our website, free of charge, as soon as reasonably practicable after we electronically file or furnish the reports with the Securities and Exchange Commission (“**SEC”**) or with the Australian Securities Exchange (“**ASX”**). The SEC maintains an internet site, www.sec.gov, which contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. Copies of announcements made by the Company to the ASX are available on ASX’s website (www.asx.com.au).

### Corporate History

AVITA Medical, the former parent company of the AVITA Group, began as a laboratory spin-off in the Australian State of Western Australia. Clinical Cell Culture (C3) (being the prior name of AVITA Medical) was formed under the laws of the Commonwealth of Australia in December 1992 and has operated as AVITA Medical since 2008. AVITA Medical’s ordinary shares originally began trading in Australia on the Australian Securities Exchange (“**ASX”**) on August 9, 1993. AVITA Medical’s American Depositary Shares (“**ADSs”**) traded over the counter on the OTCQX under the ticker symbol “AVMXY” from May 14, 2012 through September 30, 2019 and its ADSs began trading on the NASDAQ on October 1, 2019, under the ticker symbol “RCEL”.

The Company’s CDI’s are quoted on the ASX under AVITA Medical’s former ASX ticker code, “AVH”. The Company’s shares of common stock are quoted on NASDAQ under AVITA Medical’s former NASDAQ ticker code, “RCEL”. One share of common stock on NASDAQ is equivalent to five CDIs on the ASX.

### COVID-19 Business Update and Risks Associated with COVID-19

Beginning in the first quarter of 2020, the ongoing coronavirus (“COVID-19”) pandemic has created significant disruptions to the global economies and financial markets. In the United States, State and Local Governmental authorities have responded by issuing orders, of varying degrees, requiring quarantines, restrictions on travel, mandatory closures of certain non-essential businesses, as well as providing recommendations to minimize social gatherings or interactions. Due to such orders, the COVID-19 pandemic began impacting our operations and financial results. For example, on March 19, 2020, the Executive Department of the State of California issued Executive Order N-33-20, ordering all individuals in the State of California to stay at home or at their place of residence except as needed to maintain continuity of operations of federal critical infrastructure sectors. Our primary operations are located in Valencia and Ventura, California. In response to this order, we took certain business measures which included institution of various workplace protections to ensure the safety of our employees (e.g., wearing of masks, wiping down high touch areas, etc.), and the limiting of vendors and visitors to our facilities. Essential staff in manufacturing and limited support functions have continued to work from our locations following appropriate hygiene and social distancing protocols. To reduce the risk to our employees and their families from potential exposure to COVID-19, we limited activities at our corporate headquarters, encouraged our employees to work from home, encouraged virtual meetings, restricted non-essential business travel, made physical modifications and enhancements to our facilities to effect social distancing, and provided personal protective equipment to our employees. We also increased safety stocks of our product, established temporary satellite product storage locations, and accelerated initiatives to increase sourcing options. Once most restrictions were lifted, we resumed in-office work at our corporate headquarters during March 2022, on a hybrid work schedule for some of our employees. We also lifted the restriction on non-essential business travel as more states and countries began to lift travel restrictions. However, during July 2022, due to the resurgence in COVID-19 cases and hospitalizations in Los Angeles County due primarily to the Omicron BA.5 variant, we have resumed work from home for our employees at the corporate headquarters with essential staff and manufacturing and limited support functions continuing to work from our locations as we continue to monitor the fluid situation. Throughout the pandemic, we have remained focused on managing the business for the long-term, including maintaining our employee workforce as well as continuing to invest in critical research and development, clinical, and corporate infrastructure-related programs.

The ongoing global COVID-19 pandemic presents significant risks to us and may have far reaching impacts on our business, operations, and financial results and condition, directly and indirectly, including, without limitation, impacts on: the health of our management and employees; manufacturing, distribution, marketing and sales operations; research and development activities, including clinical activities; and customer and patient behaviors. Moreover, beginning in March 2020, access to hospitals and other customer sites was restricted to essential personnel, which negatively impacted our ability to promote the use of the RECELL System with physicians, and to enroll our clinical studies. In addition, some hospitals and other burn centers suspended the treatment of burn patients or re-distributed those patients to other treatment facilities and, together with a general reduction in broader economic activity (e.g., reduced travel, reduced mobility, suspension of certain business operations, etc.), this resulted in a reduction in the volume of burn procedures using the RECELL System in the immediate period following the implementation of those protective measures. In addition, we experienced periodic enrollment cessation in our clinical trials due to COVID-19 as well as having individuals excluded because they had contracted COVID-19.

We are continuing to monitor the impact of the COVID-19 pandemic on our employees, customers, and on the markets in which we operate. We will take further actions that we consider prudent to address the COVID-19 pandemic, including reducing spending, while ensuring that we can support our customers and continue to develop our products. The ultimate extent of the impact of the COVID-19 pandemic on us, including the discovery and spread of existing and future contagious variants to COVID-19 such as Omicron BA.5, remains highly uncertain and will depend on future developments and factors that continue to evolve. These factors, among others include the widespread vaccination of populations including recently approved booster regimens, especially in the U.S. and improvements in treatments and therapeutics for those with COVID-19, which are outside of our control, and could exist for an extended period of time even after the pandemic might end. Further imposition of quarantines, shelter-in-place and similar government orders which are outside of our control have also impacted and could continue to impact our third-party manufacturers and suppliers which could in turn adversely impact the availability or cost of materials, which could disrupt our supply chain.

**Results of Operations for the three months ended June 30, 2022 compared to the three months ended June 30, 2021.**

**The table below summarizes the results of our continuing operations for each of the periods presented (in thousands).**

|  | Three Months Ended June 30, 2022 | 2021 | Change ($) | % Change Favorable/(Unfavorable) |
| --- | ---: | ---: | ---: | ---: |
| Revenues | $8,335 | $10,304 | $(1,969) | (19%) |
| Cost of sales | (1,386) | (2,053) | 667 | 32% |
| Gross profit | 6,949 | 8,251 | (1,302) | (16%) |
| BARDA income | 551 | 440 | 111 | 25% |
| Operating expenses: |  |  |  |  |
| Sales and marketing expenses | (5,332) | (4,146) | (1,186) | (29%) |
| General and administrative expenses | (5,471) | (5,275) | (196) | (4%) |
| Research and development expenses | (3,059) | (3,974) | 915 | 23% |
| Total operating expenses | (13,862) | (13,395) | (467) | (3%) |
| Operating loss | (6,362) | (4,704) | (1,658) | (35%) |
| Interest expense | (4) | (9) | 5 | 56% |
| Other income | 109 | 2 | 107 | 5350% |
| Loss before income taxes | (6,257) | (4,711) | (1,546) | (33%) |
| Income tax expense | (4) | (7) | 3 | 43% |
| Net loss | $(6,261) | $(4,718) | $(1,543) | (33%) |

Total net revenues decreased by 19% to $8.3 million, compared to $10.3 million in the corresponding period in the prior year. The decrease in the current period revenue was driven by our recognition of $3.6 million in Biomedical Advanced Research and Development Authority (“BARDA”) related revenue in the prior year resulting from our delivery of units to managed inventory for BARDA for emergency response preparedness. Our commercial revenue in the current period increased by $1.5 million or 23%, compared to the corresponding period in the prior year. The growth in commercial revenues was largely driven by an increase in the number of customers ordering as well as the average order size for those customers.

Gross profit margin increased by 3% to 83% compared to the corresponding period in the prior year. In the prior year our gross margins were lower compared to historical periods due to the lower price point associated with units that were delivered to managed inventory for BARDA as the BARDA contract was negotiated prior to establishing a higher price point through commercialization in the United States.

BARDA income increased by 25% to $551,000, compared to $440,000 for the corresponding period in the prior year. BARDA income consisted of funding from the Biomedical Advanced Research and Development Authority, under the Assistant Secretary for Preparedness and Response, within the U.S. Department of Health and Human Services, under ongoing USG Contract No. HHSO100201500028C. BARDA income increased as a result of funding by BARDA for the pivotal trial for use of the RECELL System for soft tissue reconstruction.

Total operating expenses increased by 3% or $0.5 million to $13.9 million, compared with $13.4 million in the corresponding period in the prior year.

Sales and marketing expenses increased by 29% or $1.2 million to $5.3 million, compared to $4.1 million incurred in the corresponding period in the prior year. Higher costs in the current year were primarily attributed to an increase in pre-commercialization costs, an increase in field personnel and higher share-based compensation expenses. Increased pre-commercialization costs were incurred for planning for RECELL launches in soft tissue reconstruction and vitiligo. Higher costs for field personnel were due to additional headcount added to deepen penetration within individual customer accounts. Higher share-based compensation expenses were due to our granting of a long-term incentive plan to drive value to the business.

General and administrative expenses increased by 4% or $0.2 million to $5.5 million, compared to $5.3 million incurred in the same period in the prior year. The increase was primarily due to higher compensation costs associated with expanding our workforce to support the overall operations along with higher professional fees, partially offset by lower stock-based compensation expenses. Increased professional fees were associated with costs to further expand the capabilities in our Ventura facility. Lower share-based compensation expenses in the current quarter were driven by certain milestones being met in the prior year.

Research and development expenses decreased by 23% or $0.9 million to $3.1 million, compared to $4.0 million incurred in the same period in the prior year. Higher costs in the prior year were primarily driven by research and development costs associated with furthering the Company’s pipeline along with ramping up clinical trial costs related activities for treatment of soft tissue and vitiligo. The favorable variance is not a purposeful reduction in spending but reflects that certain programs were in lower cost phases during this quarter.

**Results of Operations for the six months ended June 30, 2022 compared to the six months ended June 30, 2021.**

**The table below summarizes the results of our continuing operations for each of the periods presented (in thousands).**

|  | Six-Months Ended June 30, 2022 | 2021 | Change ($) | % Change Favorable/(Unfavorable) |
| --- | ---: | ---: | ---: | ---: |
| Revenues | $15,874 | $19,069 | $(3,195) | (17%) |
| Cost of sales | (3,164) | (4,199) | 1,035 | 25% |
| Gross profit | 12,710 | 14,870 | (2,160) | (15%) |
| BARDA income | 1,285 | 1,010 | 275 | 27% |
| Operating expenses: |  |  |  |  |
| Sales and marketing expenses | (10,160) | (7,795) | (2,365) | (30%) |
| General and administrative expenses | (13,005) | (10,697) | (2,308) | (22%) |
| Research and development expenses | (6,679) | (8,083) | 1,404 | 17% |
| Total operating expenses | (29,844) | (26,575) | (3,269) | (12%) |
| Operating loss | (15,849) | (10,695) | (5,154) | (48%) |
| Interest expense | (4) | (12) | 8 | 67% |
| Other income | 137 | 9 | 128 | 1422% |
| Loss before income taxes | (15,716) | (10,698) | (5,018) | (47%) |
| Income tax expense | (8) | (17) | 9 | 53% |
| Net loss | $(15,724) | $(10,715) | $(5,009) | (47%) |

Total net revenues decreased by 17% to $15.9 million, compared to $19.1 million in the corresponding period in the prior year. The decrease in the current year revenue was driven by our recognition of $7.8 million in BARDA related revenue in the prior year resulting from our delivery of units to managed inventory for BARDA for emergency response preparedness. Our commercial revenue in the current year increased by $4.4 million or 39%, compared to the corresponding period in the prior year. The growth in commercial revenues was largely driven by an increase in the number of customers ordering as well as the average order size for those customers.

Gross profit margin increased by 2% to 80% compared to the corresponding period in the prior year. In the prior year our gross margins were lower compared to historical periods due to the lower price point associated with units that were delivered to managed inventory for BARDA as the BARDA contract was negotiated prior to establishing a higher price point through commercialization in the United States.

BARDA income increased by 27% to $1.3 million, compared to $1.0 million for the corresponding period in the prior year. BARDA income consisted of funding from the Biomedical Advanced Research and Development Authority, under the Assistant Secretary for Preparedness and Response, within the U.S. Department of Health and Human Services, under ongoing USG Contract No. HHSO100201500028C. BARDA income increased as a result of funding by BARDA for the pivotal trial for use of the RECELL System for soft tissue reconstruction.

Total operating expenses increased by 12% or $3.3 million to $29.9 million, compared with $26.6 million in the corresponding period in the prior year.

Sales and marketing expenses increased by 30% or $2.4 million to $10.2 million, compared to $7.8 million incurred in the corresponding period in the prior year. Higher costs in the current year were driven by an increase in salaries and benefits, increase in pre-commercialization costs, higher share-based compensation expenses and higher travel costs. Increased salaries and benefits are attributable to an increase in field personnel to further deepen the penetration within individual customer accounts, along with higher commissions due to the increase in revenues. Higher pre-commercialization costs were incurred for planning for RECELL launches in soft tissue reconstruction and vitiligo. Increased share-based compensation expenses were driven by our granting of a long-term incentive plan to drive value to the business. Higher travel costs were due to fewer COVID-19 travel restrictions in the current year.

General and administrative expenses increased by 22% or $2.3 million to $13.0 million, compared to $10.7 million incurred in the same period in the prior year. The increase was primarily driven by higher share-based compensation expenses associated with the acceleration for certain performance milestones being met in the period, along with higher compensation costs. Higher compensation costs were associated with expanding our workforce to support the overall operations along with hiring of an executive at the end of March 2021.

Research and development expenses decreased by 17% or $1.4 million to $6.7 million, compared to $8.1 million incurred in the same period in the prior year. Higher costs in the prior year were primarily driven by research and development costs associated with furthering the Company’s pipeline along with ramping up clinical trial costs related activities for treatment of vitiligo. The favorable variance is not a purposeful reduction in spending but reflects that certain programs were in lower cost phases during this period.

### Liquidity and Capital Resources

We expect to utilize cash reserves until U.S. sales of our products reach a level sufficient to fund ongoing operations. The AVITA Group has historically funded its research and development activities, and more recently its substantial investment in sales and marketing activities, through raising capital by issuing securities, and it is expected that similar funding will be obtained to provide working capital if and when required. As of June 30, 2022, the Company has sufficient cash reserves to fund operations for the next 12-months. If the Company is unable to raise capital in the future, the Company may need to curtail expenditures by scaling back certain research and development or other programs.

The following table summarizes our cash flows for the periods presented (in thousands):

*(In Thousands)*

|  | Six Months ended June 30, 2022 | June 30, 2021 |
| --- | ---: | ---: |
| Net cash used in operations | $(12,877) | $(12,536) |
| Net cash used in investing activities | (7,845) | (526) |
| Net cash provided by financing activities | 1 | 64,058 |
| Effect of foreign exchange rate on cash and cash equivalents and restricted cash | (52) | (15) |
| Net increase/(decrease) in cash and cash equivalents and restricted cash | (20,773) | 50,981 |
| Cash and cash equivalents and restricted cash at beginning of year | 55,712 | 59,966 |
| Cash and cash equivalents and restricted cash at end of year | 34,939 | 110,947 |

37

#### Six months ended June 30, 2022, and 2021.

Net cash used in operating activities was $12.9 million and $12.5 million during the six months ended June 30, 2022, and 2021, respectively. The increase was primarily driven by higher operating costs partially offset by the collection of BARDA and trade receivables outstanding in the current period.

Net cash used in investing activities was $7.9 million and $0.5 million during the six months ended June 30, 2022, and 2021, respectively. Cash flows used for investing activities was primarily attributable to our investments into marketable securities.

Net cash provided by financing activities was $1 thousand and $64.0 million during the six months ended June 30, 2022, and 2021, respectively. The decrease in cash provided by financing activities is related to proceeds from the capital raise in March 2021.

#### Capital management.

We aim to manage capital so that the Company continues as a going concern while also maintaining optimal returns to stockholders and benefits for other stakeholders. We also aim to maintain a capital structure that ensures the lowest cost of capital available to the Company. We regularly review the Company’s capital structure and seek to take advantage of available opportunities to improve outcomes for the Company and its stockholders.

For the period ended June 30, 2022, there were no dividends paid and we have no plans to commence the payment of dividends. We have no purchase commitments or long-term contractual obligations as of June 30, 2022. We have no committed plans to issue further shares on the market but will continue to assess market conditions and the Company’s cash flow requirements to ensure the Company is appropriately funded in order to pursue its various opportunities.

There is no significant external borrowing at the reporting date. Neither the Company nor any of the subsidiaries are subject to externally imposed capital requirement.

### Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements (as defined in the rules and regulations of the SEC) that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

### Commitments and Contractual Obligations

The Company does not have any contractual obligations or purchase commitments, except for lease obligations for the period ended June 30, 2022. For details of lease obligations refer to Note 6 in the consolidated financial statements.

## Controls and procedures

As filed, 1,529 characters.

### Evaluation of Disclosure Controls and Procedures

Our Chief Executive Officer and our Chief Financial Officer evaluated, with the participation of our management, the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. As of June 30, 2022, our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures, as defined in Securities Exchange Act Rule 13a-15(e) and 15d-15(e), were effective.

Our disclosure controls and procedures have been formulated to ensure (i) that information that we are required to disclose in reports that we file or submit under the Securities Exchange Act of 1934 was recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms and (ii) that the information required to be disclosed by us is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures.

### Changes in Internal Controls over Financial Reporting

There was no change in our internal controls over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the second quarter of fiscal year 2022 covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

Filed Aug 11, 2022.
Source: SEC EDGAR, the filing index for accession 0001564590-22-029124. Last ingested by Listed: Nov 14, 2026, 21:29 ET. No prices; not investment advice.
